All About Multiple Sclerosis

More MS news articles for November 2002

Oral terbutaline differentially affects cytokine (IL-10, IL-12, TNF, IFNg) release in multiple sclerosis patients and controls

http://www.elsevier.com/gej-ng/10/27/37/137/25/49/abstract.html

Journal of Neuroimmunology, Vol. 132 (1-2) (2002) pp. 189-195
Christoph Heesen a, Stefan M. Gold b,c, Justus Sondermann a, Wiebcke Tessmer a and Karl-Heinz Schulz b
a Department of Neurology, University Hospital Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany
b Department of Medical Psychology, University Hospital Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany
c Biobehavioral Medicine Program, Ruttenberg Cancer Center, Mount Sinai School of Medicine, 1425 Madison Avenue, Box 1130, New York, NY, USA

Administration of beta-receptor agonists alleviate experimental multiple sclerosis (MS) in animal models.

In this study, we investigated the effects of terbutaline (5 mg) on IL-10, IL-12, IFN-gamma and TNF-alpha production in whole blood stimulation cultures.

IL-10 and IL-12 production were significantly enhanced in controls but not in MS patients (p=0.03 and p=0.001).

Effects were not associated with an ongoing immunomodulatory therapy.

We conclude that administration of terbutaline induces anti-inflammatory (IL-10) as well as IL-12 protein production in healthy controls but not in MS patients.

Our findings might reflect a disturbed autonomic control of the immune system in MS.